Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of CoolSculpt Combining Venus Legacy Technology for Enhanced Results in Fat Reduction & Laxity of the Flanks

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who can read, understand, and sign the Informed Consent Form.~* Subjects willing and able to comply with all study requirements.~* Subjects who have pre-scheduled a body contouring procedure.~* Subjects have clearly visible fat on the flanks, which in the investigator's opinion, may benefit from the treatment.~* Subjects have not had weight change exceeding 10 pounds in the preceding month.~* Subjects agree to maintain his/her weight (i.e., within 5 pounds) by not making any major changes in their diet or lifestyle during the course of the study.~Exclusion Criteria:~* Subjects with active localized or systemic infections.~* Immuno-compromised subjects.~* Pregnant and/or lactating (All female volunteers will be advised about using birth control during the period of study).~* In the opinion of the trained clinician, subject is unwilling or unable to adhere to all study requirements, including application and follow-up visits.~* Subjects with a history of radiation therapy to the treatment area.~* Subjects with any skin pathology or condition that could interfere with evaluation or with the use of typical ancillary medical treatments or care used before, during or after treatments.~* Subject has had a surgical procedure(s) in the area of intended treatment.~* Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment.~* Subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 12 months.~* Subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.~* Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria.~* Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.~* Subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.~* Subject is taking or has taken diet pills or supplements within the past month.~* Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion).~* Subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system~* Subject has a history of hernia in the areas to be treated.~* Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- cryolipolysis (Type: ACTIVE_COMPARATOR): Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
- cryolipolysis, multipolar RF, varipulse (Type: EXPERIMENTAL): Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete